NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Immuron Limited American Depositary Shares (IMRN) Stock Analysis

Immuron Limited American Depositary Shares (IMRN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IMRN

$1.80

+$0.69 (+62.16%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMRN with… →

IMRN Key Statistics

As of Sep 4, 2026
Trading
Open
$1.81
Previous Close
$1.11
Day's Range
1.54–1.99
52-Week Range
0.68–2.39
Volume
122.44M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.52
Valuation
Market Cap
$14.53M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.88
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.60
Financials (FY)
Revenue (FY)
$7.29M+48.63%
Net Income (FY)
−$5.22M
Profit marginThe share of revenue left as profit after all costs and taxes.
−49.77%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.07M
1-Year Return
−4.76%
Dividend and dates
Avg Volume
33.55K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IMRN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+135.91%
2025−55.12%
2024−9.33%
2023−9.86%
2022−16.80%
2021−60.75%
2020+75.48%
2019−37.41%
2018+9.64%
2017 (partial year)−36.68%

As of September 4, 2026.

IMRN Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$7.29M−$5.22M−71.6%
2024$4.90M−$6.94M−141.5%
2023$1.80M−$3.79M−209.8%
2022$765.19K−$2.85M−373.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.29M$4.77M−$5.36M−$5.22M−71.6%
2024$4.90M$3.34M−$5.22M−$6.94M−141.5%
2023$1.80M$1.31M−$3.41M−$3.79M−209.8%
2022$765.19K$523.50K−$3.12M−$2.85M−373.0%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

IMRN Valuation vs Biotechnology Median

Median of 656 stocks
MetricIMRNBiotechnology medianvs median
P/S ratio1.8815.260.1x the median
Profit margin−49.77%0.00%49.8 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Immuron Limited American Depositary Shares (IMRN) at $14.53M. It is classified in the Biotechnology industry, within the Healthcare sector.

Over the past 52 weeks the price has ranged from $0.68 to $2.39. IMRN last closed at $1.80 on September 4, 2026. That is +$0.69 (+62.16%) against the previous close. The latest close sits 165.88% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $7.29M. Against the prior fiscal year total of $4.90M, that is a change of +48.63%. The same year closed with a net loss of $5.22M. Profit margin runs at −49.77%. That is 49.8 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.6.

Across the 4 fiscal years on file, revenue moves from $765.19K in 2022 to $7.29M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 1.88 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −4.76%. Measured over 5 years, that is −17.98% a year compounded. The reported beta is 0.52. Daily returns over the trailing 9 years annualize to a volatility of 305.41%.

Growth & Income

No dividend is on file for IMRN.

So far in 2026 the price is +135.91%. Across the complete calendar years on file, 2020 returned +75.48% and 2021 returned −60.75%. Of the 8 complete calendar years on file, 2 finished higher.

Peer Comparison

Immuron Limited American Depositary Shares (IMRN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Immuron Limited American Depositary Shares IMRN $14.53M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Immuron Limited American Depositary Shares has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Immuron Limited American Depositary Shares

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Visit website →